Investigating a new treatment for Waldenström Macroglobulinemia
Official title: An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of the BCL2 Inhibitor Sonrotoclax (BGB-11417) as Monotherapy and in Combination With Zanubrutinib (BGB-3111) in Patients With Waldenström Macroglobulinemia
Run by BeiGene · NCT05952037 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing a new drug called sonrotoclax to see if it can help adults with Waldenström Macroglobulinemia feel better, either on its own or with another medication, especially for those who haven't had success with other treatments.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 105 (estimated) |
| Sponsor | BeiGene Industry-sponsored |
| Drugs / interventions | zanubrutinib |
| Locations | 72 sites (Duarte, California and 71 other locations) |
| Trial ID | NCT05952037 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults with a confirmed diagnosis of Waldenström Macroglobulinemia, especially those with relapsed or refractory disease or those who have not yet received treatment.
✕Probably not a fit
Patients with central nervous system involvement by Waldenström Macroglobulinemia or those who have transformed to aggressive lymphoma may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the safety and efficacy of the BCL2 inhibitor sonrotoclax (BGB-11417) in adults with Waldenström Macroglobulinemia, both as a standalone treatment for those who have not responded to previous therapies and in combination with zanubrutinib for previously untreated patients. The study aims to determine the proportion of participants who achieve cancer remission or experience symptom improvement, as well as to monitor any adverse effects from the treatments. Approximately 105 participants will be enrolled, and the study will take place across multiple centers worldwide over a period of about 5 years.
Why it matters
Potential benefit: If successful, this treatment could provide a new effective option for patients with Waldenström Macroglobulinemia, particularly those who have not responded to existing therapies.
How similar studies have gone: While the approach of targeting BCL2 proteins is promising, this specific combination treatment is novel and has not been extensively tested in previous studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinical and definitive histologic diagnosis of WM. * Meeting ≥ 1 criterion for treatment according to consensus panel criteria from the 2nd International Workshop on Waldenström's Macroglobulinemia (IWWM). * For Cohorts 1-3, refractory or relapsed disease at study entry unless participants had intolerance to the most recent therapy. Refractory disease is defined as not attaining at least a major response, or progressing while on or within 6 months of completing therapy. Relapsed disease is defined as attaining at least a major response to therapy and meeting the criteria for disease progression beyond 6 months after completing therapy. * For Cohort 4, patients must not have received prior therapy for WM (except for plasmapheresis). * Adequate organ function. Exclusion Criteria: * Central nervous system (CNS) involvement by WM. * Transformation to aggressive lymphoma, such as diffuse large B-cell lymphoma. * History of other malignancies ≤ 2 years before study entry. * Uncontrolled active systemic infection or recent infection requiring parenteral antimicrobial therapy that was completed ≤ 14 days before the first dose of the study drug. Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Where it's running
-
City of Hope National Medical Center
Duarte, California, United States Recruiting -
Colorado Blood Cancer Institute
Denver, Colorado, United States Recruiting -
Medstar Georgetown University Hospital
Washington, District of Columbia, United States Recruiting -
University of Miami
Miami, Florida, United States Recruiting -
Northwestern Medicine Cancer Center
Warrenville, Illinois, United States Recruiting -
Mission Cancer and Blood
Waukee, Iowa, United States Recruiting
Show 44 more locations
-
University of Maryland Greenebaum Comprehensive Cancer Center
Baltimore, Maryland, United States Recruiting -
Dana Farber Cancer Institute
Boston, Massachusetts, United States Recruiting -
Mayo Clinic Rochester
Rochester, Minnesota, United States Recruiting -
Hattiesburg Hematology and Oncology Clinic
Hattiesburg, Mississippi, United States Recruiting -
Memorial Sloan Kettering Cancer Center Mskcc
New York, New York, United States Recruiting -
Atrium Health Levine Cancer Institute (Lci)
Charlotte, North Carolina, United States Recruiting -
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States Recruiting -
Ut Southwestern Medical Center
Dallas, Texas, United States Recruiting -
Huntsman Cancer Institute
Salt Lake City, Utah, United States Recruiting -
Virginia Commonwealth University Massey Cancer Center
Richmond, Virginia, United States Recruiting -
University of Washington
Seattle, Washington, United States Recruiting -
Concord Repatriation General Hospital
Concord, New South Wales, Australia Recruiting -
Genesiscare North Shore
St Leonards, New South Wales, Australia Recruiting -
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia Recruiting -
Flinders Medical Centre
Bedford PK, South Australia, Australia Recruiting -
Monash Health
Clayton, Victoria, Australia Recruiting -
St Vincents Hospital Melbourne
Fitzroy, Victoria, Australia Recruiting -
Linear Clinical Research
Nedlands, Western Australia, Australia Recruiting -
Royal Perth Hospital
Perth, Western Australia, Australia Recruiting -
Cross Cancer Institute
Edmonton, Alberta, Canada Recruiting -
Lions Gate Hospital Chemotherapy Clinic
North Vancouver, British Columbia, Canada Recruiting -
Qeii Health Science Center
Halifax, Nova Scotia, Canada Recruiting -
Princess Margaret Cancer Centre
Toronto, Ontario, Canada Recruiting -
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China Recruiting -
Guangdong Provincial Peoples Hospital
Guangzhou, Guangdong, China Recruiting -
Henan Cancer Hospital
Zhengzhou, Henan, China Recruiting -
Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, China Recruiting -
Yancheng First Peoples Hospital
Yancheng, Jiangsu, China Recruiting -
Shengjing Hospital of China Medical Universityshenbei Branch
Shenyang, Liaoning, China Recruiting -
The Affiliated Hospital of Qingdao University Branch South
Qingdao, Shandong, China Recruiting -
Affiliated Zhongshan Hospital of Fudan University
Shanghai, Shanghai, China Recruiting -
The Third Peoples Hospital of Datong
Datong, Shanxi, China Recruiting -
Institute of Hematology and Hospital of Blood Disease
Tianjin, Tianjin, China Recruiting -
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China Recruiting -
The First Hospital of Jiaxing
Jiaxing, Zhejiang, China Recruiting -
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China Recruiting -
Centre Hospitalier Universitaire Damiens Hopital Sud
Amiens Cedex, France Recruiting -
Chu Clermont Ferrand Therapie Cellulaire and Hematolo
Clermontferrand, France Recruiting -
Institut Paoli Calmettes
Marseille, France Recruiting -
Hopital de La Pitie Salpetriere
Paris, France Recruiting -
Chu Hopital Lyon Sud
PierreBenite, France Recruiting -
Hopital Robert Debre
Reims, France Recruiting -
General Hospital of Athens Alexandra
Athens, Greece Recruiting -
Irccs Azienda Ospedaliero Universitaria Bologna
Bologna, Italy Recruiting
+22 more sites. See ClinicalTrials.gov for the full list.
Study contacts
- Study coordinator: Study Director
- Email: clinicaltrials@beigene.com
- Phone: 1-877-828-5568
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Zanubrutinib with bendamustine and rituximab for untreated Waldenström macroglobulinemia
This treatment will try zanubrutinib together with bendamustine and rituximab to see if it produces deep responses in people with untreated Waldenström macroglobulinemia.
-
Evaluating zanubrutinib for treating Waldenström Macroglobulinemia
This study is testing how well zanubrutinib works and how safe it is for people with Waldenström macroglobulinemia, especially those with certain genetic traits and from different backgrounds.
-
Comparing venetoclax and rituximab to ibrutinib and rituximab for treating Waldenstrom's macroglobulinemia
This study is testing whether a new combination of venetoclax and rituximab works better than the standard treatment of ibrutinib and rituximab for people with Waldenstrom's macroglobulinemia who haven't been treated before.
-
Zanubrutinib plus Lenalidomide for frail elderly with newly diagnosed PCNSL
This study tests whether a combination of zanubrutinib and lenalidomide can help frail elderly patients with newly diagnosed primary CNS lymphoma.
-
Venetoclax plus Zanubrutinib for CLL/SLL in frontline or previously treated patients
This phase II trial tests if venetoclax plus zanubrutinib can safely and effectively treat adults with chronic lymphocytic leukemia or small lymphocytic lymphoma, including those who are newly diagnosed and those who have had prior therapy.
-
MRD-guided Zanubrutinib + Sonrotoclax in new high-risk CLL/SLL
This trial tests a time-limited, MRD-guided combination therapy with zanubrutinib and sonrotoclax for adults up to 75 with previously untreated high-risk CLL/SLL.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.